Tirzepatide is a next-generation weight loss medication that targets both GLP-1 and GIP receptors for enhanced appetite control and metabolic benefits
In one study, 45 men with metabolic syndrome were given Metformin for a period of six months
You have unlimited access to clinicians through the portal for questions about side effects, progress, or dosage concerns
Binnen een substudie van het fase 2-obesitasonderzoek (Sanyal et al., 2024, Nature Medicine) werd Retatrutide onderzocht bij 98 deelnemers met een verhoogde hoeveelheid levervet (10% of meer, gemeten met MRI-PDFF)
The proportion of muscle loss relative to fat loss depends on several factors, including the rate of weight loss, protein intake, physical activity levels, and the individual's starting body composition